TabletsClinical Overview
Ondansetron Tablets (4mg) is an oral selective 5-HT3 receptor antagonist on the WHO Model List of Essential Medicines. It blocks serotonin signaling at 5-HT3 receptors in both the peripheral gastrointestinal vagal afferents and central area postrema. Indicated for prevention and management of nausea and vomiting caused by cytotoxic chemotherapy, radiation therapy, and acute gastroenteritis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water 30 minutes prior to chemotherapy or meals as directed by the physician. Can be taken with or without food.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, constipation, fatigue, drowsiness, transient sensation of flushing. Rare/Severe: Prolonged QT interval, arrhythmia, and serotonin syndrome.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in patients taking apomorphine. Caution in patients with cardiac conduction disorders or severe hepatic impairment.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Ondansetron Injection 2mg per ml
Ondansetron Injection (2mg/ml) is an intravenous/intramuscular selective 5-HT3 receptor antagonist on the WHO Model List of Essential Medicines. It blocks serotonin 5-HT3 receptors located centrally in the area postrema / chemoreceptor trigger zone (CTZ) and peripherally on vagal nerve terminals in the gastrointestinal tract, halting the emetic reflex cascade. Indicated for prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), radiation-induced emesis, and postoperative nausea and vomiting (PONV).
Ondansetron Oral Solution 2 mg per 5ml
Ondansetron Orally Disintegrating Formulations (4mg/8mg ODT, Oral Disintegrating Strips, and 2mg/5ml Solution) is a fast-acting 5-HT3 receptor antagonist designed for immediate buccal absorption without requiring water. It blocks peripheral vagal serotonin receptors in the gut and central CTZ receptors. Indicated for prevention of nausea and vomiting associated with cancer chemotherapy, radiotherapy, gastroenteritis-associated emesis in pediatric patients, and postoperative recovery.
Ondansetron Orally disintegrating Tablets 8mg
Ondansetron Orally Disintegrating Formulations (4mg/8mg ODT, Oral Disintegrating Strips, and 2mg/5ml Solution) is a fast-acting 5-HT3 receptor antagonist designed for immediate buccal absorption without requiring water. It blocks peripheral vagal serotonin receptors in the gut and central CTZ receptors. Indicated for prevention of nausea and vomiting associated with cancer chemotherapy, radiotherapy, gastroenteritis-associated emesis in pediatric patients, and postoperative recovery.
Ondansetron 4mg Oral Disintegrating Strips
Ondansetron Orally Disintegrating Formulations (4mg/8mg ODT, Oral Disintegrating Strips, and 2mg/5ml Solution) is a fast-acting 5-HT3 receptor antagonist designed for immediate buccal absorption without requiring water. It blocks peripheral vagal serotonin receptors in the gut and central CTZ receptors. Indicated for prevention of nausea and vomiting associated with cancer chemotherapy, radiotherapy, gastroenteritis-associated emesis in pediatric patients, and postoperative recovery.